You are here

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

Last updated on October 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Upland, California, 91786 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- The subject has a history of inadequate response to at least 1, but no more than 4,
of the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide,
cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Current Therapy With Any DMARD Or Biologic

NCT00147498
Pfizer
Completed
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Rheumatoid Arthritis
NCT03703817
All Genders
19+
Years
Multiple Sites
Systemic Lupus Erythematosus, Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
Official Title  ICMJE A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis
Brief SummaryThe study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Rheumatoid Arthritis
Intervention  ICMJE
  • Drug: CP-690,550
    Oral tablets administered at a dose of 5 mg BID for 6 weeks
  • Drug: CP-690,550
    Oral tablets administered at a dose of 15 mg BID for 6 weeks
  • Drug: CP-690,550
    30 mg BID for 6 weeks
  • Other: Placebo
    Placebo tablets
Study Arms  ICMJE
  • Experimental: 5 mg BID
    CP 690,550 5 mg BID
    Intervention: Drug: CP-690,550
  • Experimental: 15 mg BID
    CP 690,550 15 mg BID
    Intervention: Drug: CP-690,550
  • Experimental: 30 mg BID
    Oral tablets administered at a dose of 30 mg BID for 6 weeks
    Intervention: Drug: CP-690,550
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Other: Placebo
Publications *


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 7, 2012)
264
Original Enrollment  ICMJE
 (submitted: September 2, 2005)
312
Actual Study Completion Date  ICMJE June 2006
Actual Primary Completion DateJune 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • The subject has a history of inadequate response to at least 1, but no more than 4, of the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide, cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)

Exclusion Criteria:

  • Current Therapy With Any DMARD Or Biologic
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Brazil,   Canada,   Germany,   Italy,   Mexico,   Slovakia,   Spain,   United States
Removed Location CountriesAustria
 
Administrative Information
NCT Number  ICMJE NCT00147498
Other Study ID Numbers  ICMJE A3921019
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateDecember 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now